Related Experiment Video
Updated: May 10, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
Alternative splicing for diseases, cancers, drugs, and databases
Jen-Yang Tang1, Jin-Ching Lee, Ming-Feng Hou
1Department of Radiation Oncology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Alternative splicing dysregulation is linked to diseases like cancer. Correcting alternative splicing offers a therapeutic strategy, with several drugs and natural products showing potential in modulating these processes for cancer treatment.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- Alternative splicing is a key process for generating protein diversity from a limited genome.
- Dysregulation of alternative splicing is implicated in various diseases, notably cancer.
- Targeting spliceosomes represents a promising avenue for novel cancer therapeutics.
Purpose of the Study:
- To review diseases associated with alternative splicing dysregulation, focusing on cancer.
- To analyze the effects of clinical drugs, natural products, and derivatives on alternative splicing.
- To discuss other agents that modulate alternative splicing in cancer therapy.
Main Methods:
- Literature review of alternative splicing-related diseases and their target genes.
- Analysis of existing data on drugs and natural products affecting spliceosomes and alternative splicing.
- Summary of relevant bioinformatics resources for studying alternative splicing.
Main Results:
- Identified specific cancers and their associated target genes linked to alternative splicing.
- Evaluated the impact of various compounds, including clinical drugs and natural products, on alternative splicing.
- Highlighted agents with demonstrated or potential roles in modulating alternative splicing during cancer treatment.
Conclusions:
- Alternative splicing dysregulation is a significant factor in cancer development and progression.
- Modulating alternative splicing presents a viable therapeutic strategy for cancer.
- Further research into splicing-modulating agents and bioinformatics tools is crucial for advancing cancer therapy.
Related Concept Videos
RNA Splicing
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Pre-mRNA Processing
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl guanosine). This 5’ cap helps the...
